# Sickle Cell Disease and Antimicrobial Resistance: A Systematic Review and Meta-Analysis

**Authors:** Bismark Opoku-Asare, Onyansaniba K. Ntim, Aaron Awere-Duodu, Eric S. Donkor

PMC · DOI: 10.3390/idr17020032 · 2025-04-14

## TL;DR

This study reviews how sickle cell disease patients face a higher risk of antibiotic-resistant infections due to frequent antibiotic use.

## Contribution

The first systematic review and meta-analysis on antimicrobial resistance in sickle cell disease patients.

## Key findings

- High resistance rates to penicillins and co-trimoxazole were observed in SCD patients for S. aureus and S. pneumoniae.
- SCD patients had significantly higher odds of being infected with penicillin- and erythromycin-resistant S. aureus strains.
- Most studies were of moderate quality, and geographic coverage was limited, highlighting a need for more research in high SCD burden regions.

## Abstract

Background/Objectives: Antimicrobial resistance (AMR) is increasingly rising due to antimicrobial overuse and misuse. In sickle cell disease (SCD) care, frequent antibiotic use drives the rapid emergence of AMR, threatening treatment options and patient lives. This systematic review synthesizes data on AMR with regard to SCD patients for the first time. Methods: A comprehensive database search for articles published in English was conducted in PubMed, Scopus, ScienceDirect, and Web of Science, with no restriction set for the year of publication. The DerSimonian–Laird method was applied to derive the pooled prevalence, while the Mantel–Haenszel method was used to calculate the pooled odds ratio. Results: A total of 18 eligible studies covering 3220 SCD patients published between 1996 and 2024 were included in this review. The common bacterial pathogens reported in the included studies were Streptococcus pneumoniae (10 studies), Staphylococcus aureus (10 studies), and Escherichia coli (4 studies). For S. aureus, the pooled resistance was highest for penicillins (ampicillin = 100%; penicillin = 93.64%; and amoxicillin = 77.82%) followed by cefuroxime (51.23%). The pooled prevalence of methicillin-resistant S. aureus (MRSA) was 19.30%. SCD patients had 2.89 and 2.47 times higher odds of being colonized or infected with penicillin-resistant and erythromycin-resistant S. aureus strains, respectively. For S. pneumoniae, resistance prevalence was highest for co-trimoxazole (81.1%), followed by penicillin (47.08%). The pooled prevalence of multidrug-resistant (MDR) S. pneumoniae isolates was 32.12%. The majority of the studies included (n = 14, 77.8%) were of moderate quality according to the modified STROBE checklist. Conclusions: This review reveals a high prevalence of AMR with regard to SCD patients. SCD patients have an increased risk of resistance to penicillin and co-trimoxazole across several bacterial pathogens. The limited geographical distribution of the included studies underscores the urgent need for expanded AMR research on the subject, especially in regions with high SCD burden.

## Linked entities

- **Chemicals:** penicillins (PubChem CID 2349), ampicillin (PubChem CID 6249), penicillin (PubChem CID 2349), amoxicillin (PubChem CID 33613), cefuroxime (PubChem CID 5479529), co-trimoxazole (PubChem CID 358641), erythromycin (PubChem CID 12560)
- **Diseases:** sickle cell disease (MONDO:0011382)
- **Species:** Streptococcus pneumoniae (taxon 1313), Staphylococcus aureus (taxon 1280), Escherichia coli (taxon 562)

## Full-text entities

- **Diseases:** SCD (MESH:D000755), infected (MESH:D007239)
- **Species:** Homo sapiens (human, species) [taxon 9606], Escherichia coli (E. coli, species) [taxon 562], Staphylococcus aureus (species) [taxon 1280], Streptococcus pneumoniae (species) [taxon 1313]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12026643/full.md

---
Source: https://tomesphere.com/paper/PMC12026643